{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-047544","form_type":"8-K","ticker":"QNCX","cik":"0001662774","company_name":"Quince Therapeutics, Inc.","filed_at":"2026-02-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.801107+00:00","generated_at":"2026-05-16T03:03:38.788962+00:00","sec_items":["2.02","8.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Quince Therapeutics reports $5.8M cash, $16.4M debt; engages LifeSci Capital for reverse merger","bullets":["As of Dec 31, 2025, cash and short-term investments total $17.7M; EIB Loan outstanding $16.4M.","Lead drug candidate eDSP failed NEAT trial; no other products; no meaningful operations.","Engaged LifeSci Capital on Feb 9, 2026 to evaluate strategic alternatives including reverse merger.","Common stock closing bid price below $1.00 since Jan 29, 2026; Nasdaq delisting risk.","May need bankruptcy protection if reverse merger fails; Bank has not invoked MAC clause yet."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-047544","json":"https://secwatch.observer/filing/0001193125-26-047544.json","markdown":"https://secwatch.observer/filing/0001193125-26-047544.md","text":"https://secwatch.observer/filing/0001193125-26-047544.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1662774/000119312526047544/0001193125-26-047544-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1662774/000119312526047544/d89820d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T03:03:38.788962+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}